Thompson Davis & Co’s Horizon Therapeutics Public Limited Company Ordinary Shares HZNP Stock Holding History

Thompson Davis & Co’s Portfolio HZNP Stock Details HZNP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q2	–	Sell	-179	Closed	-$3K	–	1227
2016 Q1	$3K	Hold	179	–	–	﹤0.01%	918
2015 Q4	$4K	Buy	+179	New	+$3.48K	0.01%	909
2015 Q3	–	Sell	-250	Closed	-$9K	–	1294
2015 Q2	$9K	Buy	+250	New	+$7.63K	0.01%	755
2015 Q1	–	Sell	-6,500	Closed	-$84K	–	1305
2014 Q4	$84K	Buy	+6,500	New	+$81.4K	0.1%	205
2014 Q3	–	Sell	-26,250	Closed	-$415K	–	1289
2014 Q2	$415K	Buy	26,250 +21,250	+425%	+$303K	0.6%	36
2014 Q1	$76K	Buy	+5,000	New	+$56.5K	0.13%	194

Other funds holding HZNP

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

KCM

Kingdon Capital Management New York $976M AUM 66.76% 1-Year Est. Return

JHIU

Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return

TCM

TimesSquare Capital Management New York $6.8B AUM 45.85% 1-Year Est. Return

Thompson Davis & Co's HZNP Position: Q2 2016 in Review

Thompson Davis & Co sold out of Horizon Therapeutics Public Limited Company Ordinary Shares (HZNP) in Q2 2016, closing a stake of 179 shares — an estimated $3K sold.

Thompson Davis & Co first reported a position in HZNP in Q1 2014 and held it in 6 quarters. The position peaked at $415K in Q2 2014. 198 funds tracked by Wall St. Rank hold HZNP as of Q2 2016.

Thompson Davis & Co reported no remaining Horizon Therapeutics Public Limited Company Ordinary Shares position as of Q2 2016 after selling out during the quarter.
Thompson Davis & Co sold 179 Horizon Therapeutics Public Limited Company Ordinary Shares shares in Q2 2016, an estimated $3K.
Thompson Davis & Co first reported a position in Horizon Therapeutics Public Limited Company Ordinary Shares in Q1 2014 and held it in 6 quarters.
Thompson Davis & Co's Horizon Therapeutics Public Limited Company Ordinary Shares position peaked at $415K in Q2 2014.
198 funds tracked by Wall St. Rank held Horizon Therapeutics Public Limited Company Ordinary Shares as of Q2 2016.

Based on Thompson Davis & Co's 13F filing for Q2 2016, filed 9 Aug 2016.